Influence of mineral metabolism parameters on pulse pressure in healthy subjects

Clinical Nephrology

Volumn 66, Issue 6, 2006, Pages 411-417

  Muray, S ^a   Marco, M P ^a,c   Craver, L ^a   Rue, M ^b   Valdivielso, J M ^b   Fernandez, E ^a,b  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b UNIVERSITY OF LLEIDA   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

Ca P product; Calcification; Cardiovascular diseases; Cockroft; Occult chronic kidney disease; Parathormone; Phosphorus; PTH; Pulse pressure; Vitamin D

Indexed keywords

CALCIFEDIOL; CALCIUM; CREATININE; MINERAL; PARATHYROID HORMONE; PHOSPHORUS; RESTRICTION ENDONUCLEASE; VITAMIN D RECEPTOR;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CALCIUM BLOOD LEVEL; CAUCASIAN; CHI SQUARE TEST; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; ETHNIC DIFFERENCE; FEMALE; FREQUENCY ANALYSIS; GENOTYPE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MINERAL METABOLISM; MULTIVARIATE ANALYSIS; NORMAL HUMAN; PHOSPHATE BLOOD LEVEL; PREDICTION; PREVALENCE; PULSE PRESSURE; SEX DIFFERENCE; VITAMIN BLOOD LEVEL;

EID: 33845415247     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp66411     Document Type: Article

References (23)

1. Amann K. Törnig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, Szabo A, Ritz E. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int. 2003; 63: 1296-1301.
2. Benets A, Rudnichi A, Safar M, Guize L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension. 1998; 32: 560-564.
3. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patient: recommendations for a change in management. Am J Kidney Dis. 2000; 35: 1226-1237.
4. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41: 1-12.
5. Domanski M, Mitchell G, Pfeffer M, Neaton JD, Norman J, Svendsen K, Grimm R, Cohen J, Stamler J. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the multiple risk factor intervention trial (MRFIT). JAMA. 2002; 287: 2677-2683.
6. Franklin SS, Khan SA, Wang ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation. 1999; 100: 354-360.
7. Jespersen B, Randlov A, Abrahamsen J, Fogh-Andersen N, Olsen NV, Kanstrup IL. Acute cardiovascular effect of 1.25-dihydroxycholecalciferol in essential hypertension. Am J Hypertens. 1999; 12: 332.
8. Jones D, Basile J, Cushman W, Egan B, Ferrario C, Hill M, Lackland D, Mensah G, Moore M, Ofili E, Roccella EJ, Smith R, Taylor H. Managing hypertension in the Southeastern United States: applying the guidelines from the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Am J Med Sci. 1999; 318: 357-364.
9. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87: E10-E17.
10. Klassen PS, Lowrie EG, Reddan DN, Delong ER, Coladonato JA, Szczech LA, Lazarus JM, Owen WF. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA. 2002; 287: 1548-1555.
11. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant. 2002; 17: 1713-1724.
12. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernandez E. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int. 2003; 85: 111-114.
13. Mourad JJ, Panier B, Blacher J, Rudnichi A, Benetos A, London GM, Safar E. Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int. 2001; 59: 1834-1841.
14. Muray S, Parisi E, Cardús A, Craver L, Fernández E. Influence of vitamin D receptor gene polymorphisms and 25-hydroxyvitamin D on blood pressure in apparently healthy subjects. J Hypertens. 2003; 21: 2069-2075.
15. Nelson DA, Vande Vord PJ, Wooley PH. Polymorphism in the vitamin D receptor gene and bone mass in African-American and white mothers and children: a preliminary report. Ann Rheum Dis. 2000; 59: 626-630.
16. Otero A, Gayoso P, Garcia F, de Francisco AL. Epidemiology of chronic renal disease in the Galician population: results of the pilot Spanish EPIRCE study. Kidney Int. 2005; Suppl 99: 16-19.
17. Sancho JJ, Rouco J, Riera-Vidal R, Sitges-Serra A. Long-term effects of parathyroidectomy for primary hyperparathyroidism on arterial hypertension. World J Surg. 1992; 16: 732-735.
18. Sowers MF, Wallace RB, Hollis BW, Lemke JH. Relationship between 1.25 dihydroxyvitamin D and blood pressure in a geographically defined population. Am J Clin Nutr. 1988; 48: 1053-1056.
19. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G and Cholesterol and Recurrent Events Trial Investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633.
20. Vaccarino V, Berger AK, Abranson J, Black HR, Setaro JF, Davey JA, Krumholz HM. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program. Am J Cardiol. 2001; 88: 980-986.
21. Van Schooten F, Hirvonen A, Maas LM, De Mol BA, Kleinjans JC, Bell DA, Durrer JD. Putative susceptibility markers of coronary artery disease: association between VDR genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue. FASEB J. 1998; 12: 1409-1417.
22. Wang MCh, Tsai WCh, Chen JY, Huang JJ. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis. 2005; 45: 494-501.
23. Yeo FE, Villines TC, Bucci JR, Taylor AJ, Abbott KC. Cardiovascular risk in Stage 4 and 5 nephropathy. Adv Chronic Kidney Dis. 2004; 11: 116-133.